Literature DB >> 30205970

Novel MprA binding motifs in the phoP regulatory region in Mycobacterium tuberculosis.

Peipei Zhang1, Jiafang Fu2, Gongli Zong3, Meng Liu4, Xiuhua Pang5, Guangxiang Cao6.   

Abstract

MprAB and PhoPR are important two-component systems (TCSs) in Mycobacterium tuberculosis, and both regulate EspR, a key regulator of the ESX-1 secretion system. Although previous studies suggest that the response regulator PhoP does not directly regulate mprA, the interplay between MprAB and PhoPR remains unclear. In this study, we found that the response regulator MprA can bind to the phoP promoter. Four repeat motifs, D1-D4, constituting two predicted binding sites, were located in the region protected by MprA in DNA footprinting. D1-D4 lack the reported conserved MprA binding sequences, indicating that MprA can recognize a greater range of target sites. Interestingly, D1-D2 overlap a previously reported PhoP binding site, and mutation of D1-D2 inhibited PhoP binding, whereas the D3-D4 site, but not the D1-D2 site, was required for MprA binding. EMSA assays also suggest that MprA and PhoP compete to bind to the phoP promoter. The results of the transcriptional and western blot assays are consistent with a model in which MprA positively controls the phoP expression, which in turn upregulates the expression of espR. These findings reveal complex regulation of a major mycobacterial TCS by dual TCSs.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  MprAB; Mycobacterium tuberculosis; PhoPR; Regulation; Two-component system

Mesh:

Substances:

Year:  2018        PMID: 30205970     DOI: 10.1016/j.tube.2018.08.002

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  1 in total

1.  One-Year Old Dormant, "Non-culturable" Mycobacterium tuberculosis Preserves Significantly Diverse Protein Profile.

Authors:  Kseniya A Trutneva; Margarita O Shleeva; Galina R Demina; Galina N Vostroknutova; Arseny S Kaprelyans
Journal:  Front Cell Infect Microbiol       Date:  2020-01-31       Impact factor: 5.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.